Endothelial Cell News 4.13 April 15, 2019 | |
| |
TOP STORYDeubiquitinase USP10 Regulates Notch Signaling in the Endothelium Scientists found that ubiquitin-specific peptidase 10 (USP10) interacted with the NOTCH1 intracellular domain (NICD1) to slow the ubiquitin-dependent turnover of this short-lived form of the activated NOTCH1 receptor. Accordingly, inactivation of USP10 reduced NICD1 abundance and stability and diminished Notch-induced target gene expression in endothelial cells. [Science] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators showed that in vitro von Willebrand factor (VWF) bound to several growth factors, including VEGF-A isoforms and platelet derived growth factor-BB, mainly through the heparin-binding domain within the VWF A1 domain. VWF also bound to VEGF-A and FGF-2 in human plasma and co-localized with VEGF-A in endothelial cells. [Blood] Abstract 3D Printing of Personalized Thick and Perfusable Cardiac Patches and Hearts The ability to print functional vascularized patches according to a patient’s anatomy was demonstrated. Blood vessel architecture was further improved by mathematical modeling of oxygen transfer. The structure and function of the patches were studied in vitro, and cardiac cell morphology was assessed after transplantation, revealing elongated cardiomyocytes with massive actinin striation. [Adv Sci] Abstract | Editorial Axitinib Exposure Triggers Endothelial Cells Senescence through ROS Accumulation and ATM Activation The authors report that axitinib, an inhibitor of VEGF receptors currently in use as a second line treatment for advanced renal cell carcinoma, promoted senescence of human endothelial cells in vitro. A one-hour pulse of axitinib was sufficient for triggering cell senescence. Mechanistically, this required oxidative stress-dependent activation of the ataxia telangiectasia mutated (ATM) kinase. [Oncogene] Abstract In a high-throughput Förster resonant energy transfer-based binding assay, researchers found that one of their synthetic analogues, with mannose as central core and galloyl substituents, exhibited higher affinity for CMG2 than the natural glucose prototype 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose and proved to be a potent angiogenesis inhibitor. [J Med Chem] Abstract | Graphical Abstract Using two-photon intravital imaging and transmission electron microscopy, scientists observed the existence of preferred sites for neutrophil entrance into the endothelial cell monolayer and exit from the basement membrane and pericyte sheath during neutrophil extravasation, namely, hotspots I and II, by elucidating distinctive roles of LFA-1 and Mac-1. [Exp Mol Med] Full Article Bone marrow and blood cells were collected for endothelial progenitor cell (EPC) analysis and mononuclear cell intracellular reactive oxygen species production, apoptosis and proliferation at baseline, day 3 and day 21 after ischemia. Cells positive for c-Kit+/CD31+ or Sca-1+/Flk-1+ or CD34+/CD133+ or CD34+/Flk-1+ were identified as EPCs. [J Cell Mol Med] Full Article The authors found that FG-4592 promoted tube formation in an in vitro model of angiogenesis by stabilizing hypoxia-inducible factor-1α and activating VEGF. When FG-4592 immobilized fibrin gel scaffold was implanted into a subcutaneous tissue engineering chamber, the vascularization process was significantly enhanced through the similar mechanisms which was verified in vitro. [Sci Rep] Full Article Secreted Ly-6/uPAR Related Protein-1 (SLURP1) suppressed the primary human neutrophil chemotaxis, and interaction with HUVECs. Furthermore, SLURP1 suppressed formyl Met-Leu-Phe-induced phosphorylation of protein kinase-B in differentiated neutrophil-like HL-60 cells. [Sci Rep] Full Article Platelet lysate (PL) exerted a protective effect on HUVECs in an inflammatory milieu by inhibiting IL-1α-activated NF-κB pathway and by inducing the secretion of PGE2, a pro-resolving molecule in the wound microenvironment. Moreover, PL enhanced HUVEC proliferation, without affecting their capability of forming tube-like structures on matrigel, and activated resting quiescent cells to re-enter cell cycle. [Cells] Abstract Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & Cell Therapy News. | |
| |
REVIEWSArterial Lymphatics in Atherosclerosis: Old Questions, New Insights, and Remaining Challenges The authors provide an overview of factors and mechanisms that regulate lymphangiogenesis, summarize recent findings on the role of lymphatics in macrophage reverse cholesterol transport, immune cell trafficking and pathogenesis of atherosclerosis, and present an overview of pharmacological and genetic strategies to modulate lymphatic vessel density in cardiovascular tissue. [J Clin Med] Abstract Visit our reviews page to see a complete list of reviews in the endothelial cell research field. | |
| |
INDUSTRY NEWSTRACON Pharmaceuticals announced that its Phase III TAPPAS trial evaluating TRC105 in combination with Votrient in patients with advanced or metastatic angiosarcoma was terminated for futility based on the recommendation of the Independent Data Monitoring Committee following its review of interim unblinded safety and efficacy data from more than 120 patients enrolled in the trial at the time of the analysis. [TRACON Pharmaceuticals, Inc.] Press Release Hemostemix Inc. announced that it has reached an enrollment milestone in its continuing Phase II Clinical Trial for critical limb ischemia (CLI). The company’s patented ACP-01 autologous stem cells have been shown in previous clinical studies to stimulate the generation of new blood vessels in CLI patients and improve amputation-free survival. [Hemostemix Inc.] Press Release Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD Adverum Biotechnologies, Inc. provided a program update on ADVM-022, a novel, single-administration gene therapy being evaluated in the OPTIC Phase I clinical trial in patients with wet age-related macular degeneration (wet AMD). [Adverum Biotechnologies, Inc.] Press Release Novartis announced that the FDA accepted the company’s Biologics License Application for brolucizumab for the treatment of wet age-related macular degeneration (AMD), also known as neovascular AMD, or nAMD. Seeking to make brolucizumab available as quickly as possible, Novartis used a priority review voucher to expedite FDA review. [Novartis AG] Press Release | |
| |
POLICY NEWSIndonesian Mega-Science Agency in the Balance as Election Begins Indonesians will vote in a national election that pits two old rivals against each other. The stakes are high for science. President Joko Widodo says that if he is re-elected, he will overhaul how much of the country’s research is organized and funded. The main opposition candidate has been silent on science so far. [Nature News] Editorial African Research Projects Are Failing Because Funding Agencies Can’t Match Donor Money Although African countries appreciate research grants from donor countries, they often chafe at the condition that they bring in their own money in order to be eligible. Some research projects fall by the wayside because African granting agencies simply have no way to provide their share of the money, sometimes called counterfunding, the heads of 15 national science councils in Africa said at a meeting. [ScienceInsider] Editorial
| |
EVENTSNEW Advanced Cell Therapies and Tissue Engineering Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Lead Scientist – Cell Phenotyping (Victor Chang Cardiac Research Institute) NEW Postdoctoral Position – Angiogenesis & Vascular Biology (Johns Hopkins University) Postdoctoral Position – Vascular Tissue Engineering (BioTis) Postdoctoral Position – Vascular Development (University of Massachusetts Medical School) Postdoctoral Research Scientist – Regulatory Pathways During Development (Oxford University) Postdoctoral Position – Vascular Biology (Albert Einstein College of Medicine) Faculty Position – Bioengineering (University of Pittsburgh) Assistant/Associate Adjunct Professor – Cardiovascular Medicine (UC Davis) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Endothelial Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|